Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Up 449.2% in March

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 4,987 shares, a growth of 449.2% from the March 15th total of 908 shares. Currently, 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 16,938 shares, the short-interest ratio is presently 0.3 days.

Bolt Biotherapeutics Trading Up 8.9%

Bolt Biotherapeutics stock traded up $0.40 during mid-day trading on Friday, hitting $4.91. 24,831 shares of the company’s stock were exchanged, compared to its average volume of 19,574. The firm has a market capitalization of $9.43 million, a P/E ratio of -0.28 and a beta of 0.86. Bolt Biotherapeutics has a fifty-two week low of $3.91 and a fifty-two week high of $9.25. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.76. The company’s 50 day simple moving average is $4.70 and its 200-day simple moving average is $5.26.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($3.84) EPS for the quarter, topping the consensus estimate of ($4.27) by $0.43. The business had revenue of $2.50 million for the quarter, compared to the consensus estimate of $0.67 million. Bolt Biotherapeutics had a negative return on equity of 92.54% and a negative net margin of 433.74%. On average, equities analysts anticipate that Bolt Biotherapeutics will post -1.61 earnings per share for the current year.

Institutional Trading of Bolt Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of BOLT. Squarepoint Ops LLC raised its stake in shares of Bolt Biotherapeutics by 19.8% in the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after purchasing an additional 2,448 shares during the period. Shay Capital LLC acquired a new stake in shares of Bolt Biotherapeutics in the third quarter valued at about $85,000. Susquehanna International Group LLP acquired a new stake in shares of Bolt Biotherapeutics in the third quarter valued at about $89,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at about $112,000. Finally, T3 Companies LLC acquired a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at about $208,000. Institutional investors and hedge funds own 86.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on BOLT shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Bolt Biotherapeutics in a research report on Friday, March 13th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $34.00.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.